Skip to main content
NCBI home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1978 Jun;3:281–285.

Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.

H D Kogelnik, J H Meyer, K Jentzsch, T Szepesi, K H Kärcher, E Maida, B Mamoli, P Wessely, F Zaunbauer
PMCID: PMC2149409  PMID: 209810

Abstract

Since April 1976 we have performed clinical investigations with multiple doses of the hypoxic cell radiosensitizer misonidazole in 21 patients. A significant side effect of the drug was the development of peripheral sensory neuropathies in 13 patients (8 mild, 5 severe) and of a transient acute organic psychosyndrome in 2 of the 5 patients with a severe polyneuropathy. The severity of the polyneuropathies is related to the total dose of misonidazole and the overall time of drug administration. Treatment schedules designed to obtain the desired sensitizing effect without neurological side effects are under investigation.

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADAMS G. E., DEWEY D. L. HYDRATED ELECTRONS AND RADIOBIOLOGICAL SENSITISATION. Biochem Biophys Res Commun. 1963 Aug 20;12:473–477. doi: 10.1016/0006-291x(63)90318-8. [DOI] [PubMed] [Google Scholar]
  2. Coxon A., Pallis C. A. Metronidazole neuropathy. J Neurol Neurosurg Psychiatry. 1976 Apr;39(4):403–405. doi: 10.1136/jnnp.39.4.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dische S., Saunders M. I., Lee M. E., Adams G. E., Flockhart I. R. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977 May;35(5):567–579. doi: 10.1038/bjc.1977.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fowler J. F., Adams G. E., Denekamp J. Radiosensitizers of hypoxic cells in solid tumors. Cancer Treat Rev. 1976 Dec;3(4):227–256. doi: 10.1016/s0305-7372(76)80012-6. [DOI] [PubMed] [Google Scholar]
  5. Fowler J. F., Sheldon P. W., Denekamp J., Field S. B. Optimum fractionation of the C3H mouse mammary carcinoma using x-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutrons. Int J Radiat Oncol Biol Phys. 1976 Jul-Aug;1(7-8):579–592. doi: 10.1016/0360-3016(76)90139-5. [DOI] [PubMed] [Google Scholar]
  6. Gray A. J., Dische S., Adams G. E., Flockhart I. R., Foster J. L. Clinical testing of the radiosensitiser Ro-07-0582. I. Dose tolerance, serum and tumour concentrations. Clin Radiol. 1976 Apr;27(2):151–157. doi: 10.1016/s0009-9260(76)80137-7. [DOI] [PubMed] [Google Scholar]
  7. Johnson R., Gomer C., Ambrus J., Pearce J., Boyle D. Letter: An investigation of the pharmacological and radiosensitizing effects of the 2-nitroimidazole Ro-07-0582 in primates. Br J Radiol. 1976 Mar;49(579):294–295. doi: 10.1259/0007-1285-49-579-294-b. [DOI] [PubMed] [Google Scholar]
  8. Thomlinson R. H., Dische S., Gray A. J., Errington L. M. Clinical testing of the radiosensitiser Ro-07-0582. III. Response of tumours. Clin Radiol. 1976 Apr;27(2):167–174. doi: 10.1016/s0009-9260(76)80139-0. [DOI] [PubMed] [Google Scholar]
  9. Urtasun R. C., Band P., Chapman J. D., Rabin H. R., Wilson A. F., Fryer C. G. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977 Mar;122(3):801–804. doi: 10.1148/122.3.801. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES